Gardiquimod 可抑制巨噬细胞和活化的外周血单个核细胞的HIV-1感染。 它是一种咪唑喹啉类似物，是一种 TLR7/8 激动剂。

Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7.

Administration of 6-60?μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis[1].

Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells[2].

1020412-43-4

C17H23N5O

313.4

DMSO:18 mg/mL (57.43 mM)
DMF:18 mg/mL (57.43 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years